Literature DB >> 28786420

Cardiovascular toxicities of systemic treatments of prostate cancer: is oestrogen to the rescue?

Antonello Veccia1, Francesca Maines1, Orazio Caffo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28786420     DOI： 10.1038/nrurol.2017.127

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  7 in total

1.  Cardiovascular toxicities of systemic treatments of prostate cancer: oestrogen to the rescue?

Authors:  Syed Imran A Shah; Hannah C P Wilson; Paul D Abel
Journal:  Nat Rev Urol       Date:  2017-08-08       Impact factor: 14.432

2.  Transdermal estradiol therapy for advanced prostate cancer--forward to the past?

Authors:  J L Ockrim; E-N Lalani; M E Laniado; S St C Carter; P D Abel
Journal:  J Urol       Date:  2003-05       Impact factor: 7.450

Review 3.  Cardiovascular toxicities of systemic treatments of prostate cancer.

Authors:  Antonello Veccia; Francesca Maines; Stefania Kinspergher; Enzo Galligioni; Orazio Caffo
Journal:  Nat Rev Urol       Date:  2017-01-24       Impact factor: 14.432

4.  Quality-of-life outcomes from the Prostate Adenocarcinoma: TransCutaneous Hormones (PATCH) trial evaluating luteinising hormone-releasing hormone agonists versus transdermal oestradiol for androgen suppression in advanced prostate cancer.

Authors:  Duncan C Gilbert; Trinh Duong; Howard G Kynaston; Abdulla A Alhasso; Fay H Cafferty; Stuart D Rosen; Subramanian Kanaga-Sundaram; Sanjay Dixit; Marc Laniado; Sanjeev Madaan; Gerald Collins; Alvan Pope; Andrew Welland; Matthew Nankivell; Richard Wassersug; Mahesh K B Parmar; Ruth E Langley; Paul D Abel
Journal:  BJU Int       Date:  2016-11-12       Impact factor: 5.588

5.  Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5.

Authors:  Per Olov Hedlund; Jan-Erik Damber; Inger Hagerman; Svein Haukaas; Peter Henriksson; Peter Iversen; Robert Johansson; Peter Klarskov; Finn Lundbeck; Finn Rasmussen; Eberhard Varenhorst; Jouko Viitanen
Journal:  Scand J Urol Nephrol       Date:  2008

Review 6.  Emerging potential of parenteral estrogen as androgen deprivation therapy for prostate cancer.

Authors:  Syed Imran Ali Shah
Journal:  South Asian J Cancer       Date:  2015 Apr-Jun

7.  Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09).

Authors:  Ruth E Langley; Fay H Cafferty; Abdulla A Alhasso; Stuart D Rosen; Subramanian Kanaga Sundaram; Suzanne C Freeman; Philip Pollock; Rachel C Jinks; Ian F Godsland; Roger Kockelbergh; Noel W Clarke; Howard G Kynaston; Mahesh Kb Parmar; Paul D Abel
Journal:  Lancet Oncol       Date:  2013-03-04       Impact factor: 41.316
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.